Get the Stockscreener App
6.19
2.06%
-0.13
After Hours:
6.10
-0.09
-1.45%
Myriad Genetics Inc stock is traded at $6.19, with a volume of 1.77M.
It is down -2.06% in the last 24 hours and up +15.92% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$6.32
Open:
$6.3
24h Volume:
1.77M
Relative Volume:
0.77
Market Cap:
$575.95M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-4.7615
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
+55.53%
1M Performance:
+15.92%
6M Performance:
-50.76%
1Y Performance:
-77.85%
1-Day Range:
$6.065
$6.5199
1-Week Range:
$3.85
$6.5199
52-Week Range:
$3.76
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
6.19 | 588.04M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
462.39 | 173.97B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
199.76 | 143.61B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
652.11 | 52.65B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.13 | 32.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
180.09 | 30.58B | 15.50B | 1.33B | 2.16B | 7.34 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics outlines high single-digit to low double-digit growth target through cancer care continuum focus - MSN
TD Cowen Maintained a Hold Rating on Myriad Genetics (MYGN) - Insider Monkey
10 Best 52-Week Low Penny Stocks to Buy Now - Insider Monkey
Will Myriad Genetics Inc. rebound enough to break evenShort-Term Stock Trend Forecast Guide - Newser
What’s next for Myriad Genetics Inc. stock priceHigh Return Trade Roadmap with Setup Filters - Newser
Is Myriad Genetics Inc. meeting your algorithmic filter criteriaScalable Strategy with Chart Confirmation - Newser
Historical volatility pattern of Myriad Genetics Inc. visualizedBuy Candidate Summary Based on Fundamentals - Newser
Myriad Genetics Raises FY25 Revenue and EBITDA Forecasts, Exceeding Market Consensus - AInvest
Myriad Genetics shares fall 1.48% premarket after UBS lowered its price target to $6. - AInvest
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics 2025 Q2 Earnings Misses Targets as Net Loss Widens 800.5% - AInvest
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates - MSN
CareDx Names Nathan Smith as New CFO - AInvest
Myriad Genetics Reports 1% YoY Revenue Growth in Q2 2025 - AInvest
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha
Why Is Myriad Genetics (MYGN) Stock Soaring Today - Yahoo Finance
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet and Other Big Stocks Record Gains on Wednesday - AInvest
Shopify, Astera Labs, Myriad Genetics, Grocery Outlet And Other Big Stocks Moving Higher On Wednesday - Benzinga
Myriad Genetics Stock Soars 30.49% on Strong Q2 Earnings - AInvest
Myriad Genetics shares surge 30.49% in premarket after reporting strong Q2 earnings and raising 2025 revenue guidance. - AInvest
Myriad Genetics 2025 Q2 Earnings Deepening Losses Amid Raised Revenue Guidance - AInvest
MYRIAD GENETICS INC SEC 10-Q Report - TradingView
Myriad Genetics (MYGN) Reports Revenue Growth, Strategic Shifts - GuruFocus
Myriad Genetics: Leveraging Strategic Overhaul and Market Tailwinds for a Comeback in Precision Medicine - AInvest
Myriad Genetics Q2 2025: Unraveling Contradictions in Strategic Focus, GeneSight Performance, and Oncology Growth - AInvest
Myriad Genetics Aims for High Single-Digit to Low Double-Digit Growth through Cancer Care Continuum Focus. - AInvest
Myriad Genetics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics Updates 2025 Revenue Guidance Amid Growth - TipRanks
Myriad Genetics (MYGN) Q2 Revenue Up 6% - AOL.com
Myriad Genetics Surges After Hours on Strong Q2 Earnings and Raised Revenue Guidance - AInvest
Myriad Genetics Surges 35.67% After Hours Following Strong Q2 Earnings Beat, Raised Revenue Guidance - inkl
Hold Rating Maintained for Myriad Genetics Amid Mixed Performance and Strategic Challenges - TipRanks
Myriad Genetics Edges Past Estimates And Lifts Revenue Outlook - Finimize
Earnings call transcript: Myriad Genetics beats Q2 2025 expectations with revenue growth - Investing.com Canada
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Myriad Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Myriad: Q2 Earnings Snapshot - San Francisco Chronicle
Myriad Genetics reports Q2 adjusted EPS 5c, consensus (1c) - TipRanks
Myriad Genetics Q2 2025 slides: revenue growth accelerates, guidance raised - Investing.com
Myriad Genetics Reports Q2 Revenue Ahead of Estimates, Stock Jumps 30.6% - AInvest
Myriad Genetics earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6% - TradingView
Myriad Genetics Q2 revenue up 1% YoY, raises FY23 guidance. - AInvest
Myriad Genetics Reports Second Quarter 2025 Financial - GlobeNewswire
[8-K] Myriad Genetics Inc Reports Material Event | MYGN SEC FilingForm 8-K - Stock Titan
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum - Yahoo Finance
Prenatal care is evolving with Myriad - WFLA
Price Channel Expanding on Myriad Genetics Inc.’s ChartLow Risk Equity Screener With Results Shared - metal.it
Myriad Genetics Inc. Recovery Likely Here’s What Data ShowsLow Risk Swing Trade Opportunities Identified - metal.it
Myriad Genetics Q2 2025 Earnings: A Pivotal Moment for a Cash-Burning Biotech - AInvest
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):